UT Health San Antonio announced Friday a landmark licensing deal worth up to $114 million with a Chinese pharmaceutical company to develop new treatments for spinal cord injuries and breast cancer.
Newsroom
UT Health San Antonio announced Friday a landmark licensing deal worth up to $114 million with a Chinese pharmaceutical company to develop new treatments for spinal cord injuries and breast cancer.